Key Corporate Partnerships

In 2018, we entered into non-exclusive global collaboration agreements with Innovent and Junshi to conduct safety run-in studies to evaluate the safety of fruquintinib or surufatinib in combination with PD-1 monoclonal antibodies being developed by Innovent (Tyvyt) and Junshi (Tuoyi).